Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 111CNS 6Genitourinary 2Gastrointestinal 2Breast 2Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Carcinoma, Renal Cell 13Prostatic Neoplasms 8Urinary Bladder Neoplasms 6Kidney Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 4Neoplasm Metastasis 3Colonic Neoplasms 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Salivary Gland Neoplasms 2Rectal Neoplasms 2Neoplasms 2Lung Neoplasms 2Hereditary leiomyomatosis and renal cell cancer 2Glioma 2Esthesioneuroblastoma, Olfactory 2Ependymoma 2Wilms Tumor 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thrombocytosis 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Papillary renal cell carcinoma, sporadic 1Osteosarcoma 1Oligodendroglioma 1

Interventions

pembrolizumab 26Magnetic Resonance Spectroscopy 14Nivolumab 13Docetaxel 13Specimen Handling 11Radiotherapy 9Paclitaxel 9Radiosurgery 8Early Intervention, Educational 8Cyclophosphamide 8Gemcitabine 7atezolizumab 6Taxes 6Surveys and Questionnaires 6Standard of Care 6Psychiatric Rehabilitation 6Ipilimumab 6Carboplatin 6sargramostim 5Pemetrexed 5Methods 5motexafin gadolinium 4fludarabine 4X-Rays 4Interviews as Topic 4Immunoglobulin G 4Fluorouracil 4Educational Status 4Cisplatin 4Biopsy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lung Neoplasms × Erlotinib Hydrochloride × Genitourinary × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT01402089 2016-02-02

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Cantonal Hospital of St. Gallen

Phase 4 Completed
54 enrolled
GastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡